ERBB2 and breast cancer: HER-2 amplification is the primary pathway of HER-2 receptor overexpression and has been shown to play an important role in the development and progression of certain aggressive types of BC, such as lobular cancer in situ (LCIS) or invasive ductal carcinoma (IDC) to a lesser degree.